ArticleJournal of molecular biology2012

Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.

Jamie B Spangler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.